Search results for "Pie"

showing 10 items of 4404 documents

Regional Intestinal Drug Permeability and Effects of Permeation Enhancers in Rat

2020

Sufficient colonic absorption is necessary for all systemically acting drugs in dosage forms that release the drug in the large intestine. Preclinically, colonic absorption is often investigated using the rat single-pass intestinal perfusion model. This model can determine intestinal permeability based on luminal drug disappearance, as well as the effect of permeation enhancers on drug permeability. However, it is uncertain how accurate the rat single-pass intestinal perfusion model predicts regional intestinal permeability and absorption in human. There is also a shortage of systematic in vivo investigations of the direct effect of permeation enhancers in the small and large intestine. In …

DrugKetoprofenmedia_common.quotation_subjectlcsh:RS1-441Pharmaceutical ScienceGastroenterology and Hepatology02 engineering and technologyPharmacology030226 pharmacology & pharmacyArticleDosage formlcsh:Pharmacy and materia medicaJejunumPharmaceutical Sciences03 medical and health sciences0302 clinical medicineabsorption-modifying excipientsintestinal perfusionIn vivoGastroenterologimedicineLarge intestineregional intestinal permeabilitymedia_commonIntestinal permeabilityChemistrypermeation enhancersPermeationFarmaceutiska vetenskaper021001 nanoscience & nanotechnologymedicine.diseasepharmaceutical developmentmedicine.anatomical_structureoral peptide delivery0210 nano-technologymedicine.drugPharmaceutics
researchProduct

Biowaiver monograph for immediate-release solid oral dosage forms: fluconazole.

2014

Literature data pertaining to the decision to allow a waiver of in vivo bioequivalence (BE) testing requirements for the approval of immediate release (IR) solid oral dosage forms containing fluconazole as the only active pharmaceutical ingredient (API) are reviewed. The decision is based on solubility, dissolution, permeability, therapeutic index, pharmacokinetic parameters, pharmacodynamic properties, and other relevant data. BE/bioavailability (BA) problems and drug-excipients interaction data were also reviewed and taken into consideration. According to the biopharmaceutics classification system (BCS), fluconazole in polymorphic forms II and III is a BCS class I drug and has a wide ther…

DrugMalemedia_common.quotation_subjectChemistry PharmaceuticalPharmaceutical ScienceAdministration OralBiological AvailabilityPharmacologyBioequivalenceDosage formPermeabilityBiopharmaceuticsExcipientsPharmacokineticsmedicineHumansFluconazolemedia_commonRandomized Controlled Trials as TopicActive ingredientDosage FormsCross-Over StudiesChemistryBiopharmaceutics Classification SystemBioavailabilitySolubilityTherapeutic EquivalencyFemaleFluconazolemedicine.drugJournal of pharmaceutical sciences
researchProduct

Biowaiver Monographs for Immediate-Release Solid Oral Dosage Forms: Nifedipine

2015

Literature data relevant to the biopharmaceutical properties of the active pharmaceutical ingredient (API) nifedipine are reviewed to evaluate whether a waiver of in vivo bioequivalence (BE) testing of immediate-release (IR) dosage forms formulated as tablets and soft gelatin capsules is warranted. Nifedipine's solubility and permeability, its therapeutic use and index, pharmacokinetics, food drug interactions, and any reported BE/bioavailability problems were all taken into consideration. Solubility and BA data indicate conclusively that nifedipine is a class II substance of biopharmaceutics classification system (BCS) and that the formulation of drug product plays a key role on the dissol…

DrugNifedipineChemistry Pharmaceuticalmedia_common.quotation_subjectPharmaceutical ScienceCapsulesBioequivalencePharmacologyDosage formExcipientsFood-Drug InteractionsNifedipinePharmacokineticsmedicineAnimalsHumansmedia_commonActive ingredientChemistryCalcium Channel BlockersBiopharmaceutics Classification SystemBioavailabilityIntestinal AbsorptionSolubilityTabletsmedicine.drugJournal of Pharmaceutical Sciences
researchProduct

Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Aciclovir

2008

Literature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing (biowaiver) for the approval of immediate release (IR) solid oral dosage forms containing aciclovir are reviewed. Aciclovir therapeutic use and therapeutic index, pharmacokinetic properties, data related to the possibility of excipient interactions and reported BE/bioavailability (BA) studies were also taken into consideration in order to ascertain whether a biowaiver can be recommended. According to the Biopharmaceutics Classification System (BCS) and considering tablet strengths up to 400 mg, aciclovir would be BCS Class III. However, in some countries also 800 mg tablets are available which …

Drugbusiness.industrymedia_common.quotation_subjectAcyclovirAdministration OralBiological Availabilityvirus diseasesPharmaceutical ScienceExcipientPharmacologyBioequivalenceBiopharmaceutics Classification SystemAntiviral AgentsDosage formTherapeutic EquivalencyPharmacokineticsmedicineRegulatory scienceAciclovirbusinessmedicine.drugmedia_commonJournal of Pharmaceutical Sciences
researchProduct

Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Metformin Hydrochloride.

2021

Abstract Data are examined regarding possible waiver of in vivo bioequivalence testing (i.e. biowaiver) for approval of metformin hydrochloride (metformin) immediate-release solid oral dosage forms. Data include metformin's Biopharmaceutics Classification System (BCS) properties, including potential excipient interactions. Metformin is a prototypical transporter-mediated drug and is highly soluble, but only 50% of an orally administered dose is absorbed from the gut. Therefore, metformin is a BCS Class III substance. A BCS-based approval approach for major changes to marketed products and new generics is admissible if test and reference dosage forms have the identical active pharmaceutical …

Drugendocrine system diseasesmedia_common.quotation_subjectPharmaceutical ScienceExcipientAdministration OralBiological Availabilitytransporters02 engineering and technologyPharmacologyBioequivalence030226 pharmacology & pharmacyDosage formPermeabilityBiopharmaceutics03 medical and health sciencesMetformin hydrochloride0302 clinical medicinePharmacokineticsmedicineBiopharmaceutics Classification System (BCS)media_commonActive ingredientDosage FormsbioequivalenceexcipientsChemistry021001 nanoscience & nanotechnologyBiopharmaceutics Classification SystembiowaiverMetforminMetforminSolubilityTherapeutic Equivalencyregulatory science0210 nano-technologypharmacokineticsmedicine.drugJournal of pharmaceutical sciences
researchProduct

Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Carbamazepine.

2020

Abstract Literature relevant to assessing whether BCS-based biowaivers can be applied to immediate release (IR) solid oral dosage forms containing carbamazepine as the single active pharmaceutical ingredient are reviewed. Carbamazepine, which is used for the prophylactic therapy of epilepsy, is a non-ionizable drug that cannot be considered “highly soluble” across the range of pH values usually encountered in the upper gastrointestinal tract. Furthermore, evidence in the open literature suggests that carbamazepine is a BCS Class 2 drug. Nevertheless, the oral absolute bioavailability of carbamazepine lies between 70 and 78% and both in vivo and in vitro data support the classification of ca…

Drugmedia_common.quotation_subjectPharmaceutical ScienceAdministration OralBiological Availability02 engineering and technologyBioequivalencePharmacology030226 pharmacology & pharmacyDosage formBiopharmaceuticsExcipients03 medical and health sciences0302 clinical medicineIVIVCTherapeutic indexmedicineImmediate releasemedia_commonActive ingredientDosage Formsbusiness.industryCarbamazepine021001 nanoscience & nanotechnologyCarbamazepineSolubilityTherapeutic Equivalency0210 nano-technologybusinessmedicine.drugJournal of pharmaceutical sciences
researchProduct

Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Cephalexin Monohydrate.

2019

Literature data and results of experimental studies relevant to the decision to allow waiver of bioequivalence studies in humans for the approval of immediate release solid oral dosage forms containing cephalexin monohydrate are presented. Solubility studies were performed in accordance with the current biowaiver guidelines of the Food and Drug Administration, World Health Organization and European Medicines Agency, taking the degradation at some pH values into consideration. Together with solubility and permeability data for cephalexin monohydrate from the literature, it was demonstrated to be a Biopharmaceutics Classification System Class 1 drug. The pharmacokinetic behavior, results of b…

Drugmedia_common.quotation_subjectPharmaceutical ScienceExcipientAdministration OralBiological Availability02 engineering and technologyBioequivalencePharmacology030226 pharmacology & pharmacyDosage formPermeabilityBiopharmaceutics03 medical and health sciences0302 clinical medicinemedicineBiopharmaceutics Classification System (BCS)HumansRegulatory scienceLADME characteristicsmedia_commonActive ingredientcephalexin monohydrateDosage FormsbioequivalenceCephalexinexcipientsbusiness.industryBiopharmaceutics021001 nanoscience & nanotechnologyBiopharmaceutics Classification SystemSolubilityTherapeutic Equivalencyregulatory science0210 nano-technologybusinessmedicine.drugJournal of pharmaceutical sciences
researchProduct

Adverse drug reactions in some African herbal medicine: literature review and stakeholders’ interview

2014

International audience; Background: In view of the large consumption of herbal medicine in Africa countries, it is likely that many adverse drugs reactions go unrecorded with either patients failing to present to health services, or no pharmacovigilance analysis being made, or the analysis not being reported centrally. This problem is of interest especially for those who are working in the general area of adverse drug reactions or stakeholders in the domain of herbal medicine for considering safety issues. Methods: We are particularly interested in the way that the use of very wellknown and highly valued plants is linked to the observation of adverse drug reactions in African countries. We …

Drugmedicine.medical_specialtyAlternative medicinesmedia_common.quotation_subjectAlternative medicineMédecine humaine et pathologieReview Articlealternative medicines;complementary therapies;pharmacovigilance practice;toxicological risk assesment;traditional medicinePharmacovigilance practiceToxicology and food chainOccupational safety and healthPharmacovigilanceFood and NutritionMedicine[SPI.GPROC]Engineering Sciences [physics]/Chemical and Process EngineeringDrug reactionMedicinal plantsGénie des procédéslcsh:Miscellaneous systems and treatmentsToxicologie et chaîne alimentairemedia_commonTraditional medicinebusiness.industry[ SPI.GPROC ] Engineering Sciences [physics]/Chemical and Process EngineeringTraditional medicineToxicological risk assessmentmedicine.diseaselcsh:RZ409.7-999Complementary therapiesComplementary and alternative medicineAction (philosophy)Family medicineAlimentation et NutritionHuman health and pathologybusinessAdverse drug reactionIntegrative Medicine Research
researchProduct

Memoria de lo acaecido en el exército del General Dupont : desde su entrada en Córdova en el dia 7 de junio del año 1808, hasta su rendición de resul…

Sign.: [A]4, B-E4 Notes a peu de pàg

Dupont de l'Etang Pierre-Antoine
researchProduct

Quantized Dissensus in Networks of Agents subject to Death and Duplication

2012

Dissensus is a modeling framework for networks of dynamic agents in competition for scarce resources. Originally inspired by biological cells behaviors, it fits also marketing, finance and many other application areas. Competition is often unstable in the sense that strong agents, those having access to large resources, gain more and more resources at the expense of weak agents. Thus, strong agents duplicate when reaching a critical amount of resources, whereas weak agents die when loosing all their resources. To capture all these phenomena we introduce systems with a discrete time gossip and unstable state dynamics interrupted by discrete events affecting the network topology. Invariancy o…

Dynamic ProgrammingConsensus ProtocolsComputer sciencemedia_common.quotation_subjectDistributed computingSubject (philosophy)Dynamical Systems (math.DS)Network topologyConsensus protocolScarcityCompetition (economics)Settore ING-INF/04 - AutomaticaGossipFOS: MathematicsElectrical and Electronic EngineeringMathematics - Dynamical SystemsMathematics - Optimization and Controlmedia_commonConsensus Protocols; Quantized Control; Dynamic Programming; Network based marketing; Dynamic Pie Diagram.Dynamic Pie Diagramquantized controlComputer Science ApplicationsConsensus protocolsConsensus protocols; network based marketing; quantized controlDiscrete time and continuous timeControl and Systems Engineeringnetwork based marketingOptimization and Control (math.OC)90C3993Dxx34K2034a38Settore MAT/09 - Ricerca Operativa
researchProduct